Analysts at William Blair raised their Q1 2025 EPS estimates for Nektar Therapeutics in a research report issued to clients and investors on Thursday, March 13th. William Blair analyst A. Hsieh now ...
Butterfly Network exceeded Q4 estimates with 35% revenue growth. William Blair sees strong upside, citing homecare potential ...
William Blair analyst Louie DiPalma maintained a Hold rating on Science Applications (SAIC – Research Report) today. The company’s shares ...
Equities research analysts at William Blair issued their Q1 2026 earnings estimates for shares of Sprinklr in a note issued ...
Investor's Business Daily on MSN9h
Incyte Loses 9% As Skin Disease Drug Looks 'Viable, But Not Competitive'Incyte's skin disease treatment looks "viable, but not competitive with biologics," an analyst said Monday as Incyte stock fell.
Palantir (NASDAQ:PLTR) was upgraded to Market Perform from Underperform by William Blair, following the recent share price ...
We recently compiled a list of the 10 AI Stocks Investors Are Watching Closely Right Now. In this article, we are going to ...
JPMorgan Chase & Co. has hired William Kallop from William Blair & Co. for its mergers and acquisitions group focused on ...
The firm upgraded Palantir from Underperform to Market Perform after a sharp stock decline but did not assign a price target.
William Blair downgraded Udemy (UDMY) to Market Perform from Outperform after the company announced the appointment of Hugo Sarrazin as ...
The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...
The embedded finance company, which posted a loss last year, hired Citi to explore its strategic options and named an interim ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback